TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

among hospitalized patients. Clin Infect Dis 2009;49:507-14.
5A.105 Jeffres MN et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients
with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther
2007;29:1107-15.
5A.106 Lewis MD et al. A 63-year old man with skin eruptions. Clin Infect Dis 2004;38:442-3.
5A.107 Von Drygalski A et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007;356:904-
10.
5A.108 Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin
North Am 2004;18:621-49.
5A.109 Maglio D et al. Impact of pharmacodynamics on dosing of macrolides, ketolides, and azalides. Infect
Dis Clin North Am 2003;17:563-77.
5A.110 Bradford DR et al. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity: a case
report. Ann Otol Rhinol Laryngol 2000;109:435-7.
5A.111 Kasten MJ. Clindamycin, metronidazole and chloramphenicol. Mayo Clin Proc 1999;74:825-33.
5A.112 Mishra A et al. The effects of erythromycin on the electrocardiogram. Chest 1999;115:983-6.
5A.113 Drici MD et al. Cardiac actions of erythromycin: influence of female sex. J Am Med Assoc 1998;280:
1774-6.
5A.114 Mahon BE et al. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors
for infantile hypertrophic pyloric stenosis. J Pediatr 2001;139:380-4.
5A.115 Owens RC et al. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect
Dis 2006;43:1603-11.
5A.116 Ray WA et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med
2004;351:1089-96.
5A.117 Rubinstein E et al. Spiramycin renaissance. J Antimicrob Chemother 1998;42:572-6.
5A.118 European Medicines Agency (EMA). European assessment report (EPAR). Ketek TM , summary of product
characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/ docu-ment_library/EPAR_-
_Product_Information/human/000354/WC500041895.pdf. Accessed on August 4 th 2010.
5A.119 Brown SD. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.
Drug Saf 2008;31:561-75.
5A.120 Clay KD et al. Severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern
Med 2006;144:415-20.
5A.121 Turner M et al. Telithromycin. Ann Intern Med 2006;144:447-8.
5A.122 Graham DJ. Telithromycin and acute liver failure. N Engl J Med 2006;355:2260-1.
5A.123 Roberts MC. Tetracycline therapy: update. Clin Infect Dis 2003;36:462-7.
5A.124 Smilack JD. The tetracyclines. Mayo Clin Proc 1999;74:727-9.
5A.125 El-Hallak M et al. Chronic minocycline-induced autoimmunity in children. J Pediatr 2008;153:314-9.
5A.126 European Medicines Agency (EMA). European assessment report (EPAR). Tygacil TM , summary of
product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR
_-_Product_Information/human/000644/WC500044508.pdf. Accessed on August 4th 2010.
5A.127 Stein GE et al. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-24.
5A.128 Schafer JJ et al. Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev
Anti Infect Ther 2008;6:557-67.
5A.129 Hung WY et al. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob
Agents 2009;34:486-9.
5A.130 Knueppel RC et al. Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect
Dis 2007;45:136-7.
5A.131 Löfmark S et al. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect
Dis 2010;50(suppl. 1):S16-23.
5A.132 Kasten MJ. Clindamycin, metronidazole and chloramphenicol. Mayo Clin Proc 1999;74:825-33.
5A.133 Woodruff BK et al. Reversible metronidazole induced lesions of the cerebellar dentate nuclei. N Engl
J Med 2002;346:68-9.
5A.134 Tabak F et al. Ornidazole-induced liver damage: report of three cases and review of the literature. Liver
Int 2003;23:351-4.
5A.135 Nailor MD et al. Tinidazole for bacterial vaginosis. Expert Rev Anti Infect Ther 2007;5:343-8.
5A.136 Manes G et al. Tinidazole: from protozoa to Helicobacter pylori. The past, present and future of a
nitro-imidazole with pecularities. Expert Rev Anti Infect Ther 2004;2:695-705.
5A.137 Fung HB et al. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005;27:1859-84.
5A.138 Nation RL. Colistin in the 21 st century. Curr Opin Infect Dis 2009;22:535-43.
5A.139 Paul M et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob
Chemother 2010;65:1019-27.
5A.140 Landman D et al. Polymyxins revisited. Clin Microbiol Rev 2008;21:449-65.
5A.141 Kaye D. Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect
Dis Clin North Am 2004;18:669-89.
5A.142 Hermsen ED et al. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical
applications. Infect Dis Clin North Am 2003;17:545-52.
5A.143 Li J et al. Colistin: the re-emerging antibiotic for multidrug-resistant, Gram-negative bacterial infections.
Lancet Infect Dis 2006;6:589-601.
5A.144 Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative
bacterial infections. Clin Infect Dis 2005;40:1333-41.
5A.145 Falagas ME et al. Use of international units when dosing colistin will help decrease confusion related
to various formulations of the drug around the world. Antimicrob Agents Chemother 2006;50:2274-
5.
5A.146 Li J et al. Defining the dosage units of colistin methanesulfonate: urgent need for internatio-nal harmonization.
Antimicrob Agents Chemother 2006;50:4231-2.
5A.147 Tamma PD et al. Use of colistin in children. Pediatr Infect Dis J 2009;28:534-5.
5A.148 Plachouras D et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after
intravenous administration in critically ill patients with infections caused by Gram-negative bacteria.
Antimicrob Agents Chemother 2009;53:3430-6.